anti rock2  (Bioss)

Journal: iScience

Article Title: ZXDC enhances cervical cancer metastasis through IGF2BP3 -mediated activation of RhoA / ROCK signaling

doi: 10.1016/j.isci.2023.107447

Figure Lengend Snippet:

Article Snippet: Rabbit polyclonal anti- ROCK2 , Cell Signaling Technology , Cat#8236, RRID: AB_10829468.

Techniques: Virus, Recombinant, Reporter Assay, Chromatin Immunoprecipitation, Sequencing, Gene Expression, shRNA, Software

Journal: bioRxiv

Article Title: ROCK2 Knockout Improves Proliferation Rate in a Cellular Model of Down Syndrome

doi: 10.1101/2022.10.20.513071

Figure Lengend Snippet: A . Vector map of the sgRNA Expression Vector highlighting the ROCK2A CRISPR sgRNA driven by a U6 promoter and the EGFP and Puromycin resistance coding regions linked by P2A driven by the hPGK promoter. A vector with the ROCK2B sgRNA was similarly generated. B . Cytoplasmic GFP expression of the EGFP:Puro fusion protein 24 hr post transfection of the RPE1 WT-Cas9 and RPE1 21/3-Cas9 cells. Note that the RPE1-21/3 cells (lower panel) carry a histone H3:GFP fusion and thus both the cytoplasm and nuclei of transfected cells appear green. C . Western Blot confirmation of CRISPR knockout of ROCK2. Antibody detection of ROCK2 shows that expression was eliminated in transfectants with ROCK2 sgRNA A in WT and 21/3 cells, and with ROCK2 sgRNA B in 21/3 cells (asterisks*) compared to untransfected controls (black arrows). Note that in one cell line tested labeled WT ROCK2B (lane 5), knockout of ROCK2 was unsuccessful ( < ). Actin loading controls are shown in bottom panel (white arrow).

Article Snippet: The blot was blocked in 3% milk in TBST, washed, then incubated in a 1:5000 dilution for both a ROCK2 Polyclonal Antibody (Invitrogen PA5-78291) and an anti-beta actin antibody (Proteintech 20536-1-AP).

Techniques: Plasmid Preparation, Expressing, CRISPR, Generated, Transfection, Western Blot, Knock-Out, Labeling

Journal: bioRxiv

Article Title: ROCK2 Knockout Improves Proliferation Rate in a Cellular Model of Down Syndrome

doi: 10.1101/2022.10.20.513071

Figure Lengend Snippet: Cells were plated, grown for three days, then harvested, counted and replated for a total of 12 days (see Materials and Methods). A+B . Two separate growth curve experiments for the RPE1 21/3-Cas9 and CRISPR KO cell lines. Blue, 21/3-Cas9; Red, 21/3-ROCK2A, Yellow, 21/3-ROCK2B. C . Growth curves for the RPE1 21/3-Cas9 treated with ROCK inhibitors Fasudil (purple line, triangles) and Y27632 (green line, squares). D . The increase in cell proliferation rate, expressed as a percentage of decrease in doubling time relative to the control 21/3 or WT cell line, was calculated for ROCK2 knockout and inhibitor treated aneuploid and wild type cells. See .

Article Snippet: The blot was blocked in 3% milk in TBST, washed, then incubated in a 1:5000 dilution for both a ROCK2 Polyclonal Antibody (Invitrogen PA5-78291) and an anti-beta actin antibody (Proteintech 20536-1-AP).

Techniques: CRISPR, Knock-Out